The Emerging Biologic Therapies on Food Allergy

Food allergy affects ∼8% of children and up to 5% of adults. Standard-of-care consists of food avoidance and keeping rescue epinephrine and antihistamines available.1 While oral (OIT) and/or epicutaneous immunotherapy (EPIT) products may receive FDA within the next 1-2 years, these require long-term compliance and are not known to lead a cure and may cause recurrent allergic reactions. A number of biologics has been used to treat atopic diseases and asthma but only few have been evaluated to date in food allergy (Table1).
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research